Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

2,5-Dimethoxy-4-chloroamphetamine

From Wikipedia, the free encyclopedia
Chemical compound

Pharmaceutical compound
DOC
Ball-and-stick model of the 2,5-Dimethoxy-4-chloroamphetamine molecule
Clinical data
Other namesDOC; 2,5-Dimethoxy-4-chloroamphetamine; 4-Chloro-2,5-dimethoxyamphetamine
Routes of
administration
Oral
Drug classSerotonin5-HT2 receptoragonist;Serotonergic psychedelic;Hallucinogen
Legal status
Legal status
Identifiers
  • 1-(4-Chloro-2,5-dimethoxyphenyl)propan-2-amine
CAS Number
PubChemCID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard(EPA)
ECHA InfoCard100.215.939Edit this at Wikidata
Chemical and physical data
FormulaC11H16ClNO2
Molar mass229.70 g·mol−1
3D model (JSmol)
  • ClC1=C(OC)C=C(CC(C)N)C(OC)=C1
  • InChI=1S/C11H16ClNO2/c1-7(13)4-8-5-11(15-3)9(12)6-10(8)14-2/h5-7H,4,13H2,1-3H3 checkY
  • Key:ACRITBNCBMTINK-UHFFFAOYSA-N checkY
  (verify)

2,5-Dimethoxy-4-chloroamphetamine (DOC) is apsychedelic drug of thephenethylamine,amphetamine, andDOx families. It was presumably firstsynthesized byAlexander Shulgin, and was described in his bookPiHKAL (Phenethylamines i Have Known And Loved).[2]

Recreational availability and use of DOC are rare.[3] The drug is expected to become acontrolled substance in theUnited States in the near future as of 2025.[3]

Use and effects

[edit]

A normal average dose of DOC ranges from 0.2–7.0 mg[4] the former producing threshold effects, and the latter producing extremely strong effects. Onset of the drug is 1–3 hours, peak and plateau at 4–8 hours, and a gradual come down with residual stimulation at 9-20h. After effects can last well into the next day.[4][5]

Unlike simple amphetamines, DOC is considered a chemical that influences cognitive and perception processes of the brain. The strongest supposed effects include open andclosed eye visuals, increased awareness of sound and movement, and euphoria. In the autobiography PiHKAL, Alexander Shulgin included a description of DOC as "anarchetypalpsychedelic" (#64); its presumed full-range visual, audio, physical, and mental effects show exhilarating clarity, and some overwhelming, humbling, and "composting"/interweaving effects.[5]

Toxicity

[edit]

Very little data exists about the toxicity of DOC. In April 2013, a case of death due to DOC was reported. The source does not specify whether the drug alone caused the death.[6] In 2014, a death was reported in which DOC was directly implicated as the sole causative agent in the death of a user. The autopsy indicatedpulmonary edema and asubgaleal hemorrhage.[7]

Interactions

[edit]
See also:Psychedelic drug § Interactions, andTrip killer § Serotonergic psychedelic antidotes

Pharmacology

[edit]

Pharmacodynamics

[edit]

Actions

[edit]
DOC activities
TargetAffinity (Ki, nM)
5-HT1A5,353–>9,200 (Ki)
>10,000 (EC50Tooltip half-maximal effective concentration)
<10% (EmaxTooltip maximal efficacy)
5-HT1BND
5-HT1DND
5-HT1END
5-HT1FND
5-HT2A1.4–12 (Ki)
0.6–11 (EC50)
58–102% (
Emax)
5-HT2B32 (Ki)
46 (EC50)
83% (
Emax)
5-HT2C2–143 (Ki)
15 (EC50)
97% (
Emax)
5-HT3ND
5-HT4ND
5-HT5AND
5-HT6ND
5-HT7ND
α1A>1,000
α1Bα1DND
α2A>1,000
α2Bα2CND
β1β3ND
D1ND
D2>1,000
D3D5ND
TAAR1>1,000
SERTTooltip Serotonin transporter>10,000 (Ki)
>8,600 (IC50Tooltip half-maximal inhibitory concentration)
Minimal (EC50)
NETTooltip Norepinephrine transporter>7,700 (Ki)
>8,400 (IC50)
Minimal (
EC50)
DATTooltip Dopamine transporter>10,000 (Ki)
>10,000 (IC50)
Minimal (
EC50)
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified.Refs:[8][9][10][11]

DOC acts as aserotonin5-HT2A and5-HT2C receptoragonist. Its psychedelic effects are mediated via its actions on the 5-HT2A receptor.[citation needed]

The drug is inactive as amonoamine releasing agent andreuptake inhibitor.[10]

Effects

[edit]

DOC produces thehead-twitch response, a behavioral proxy ofpsychedelic-like effects, in rodents.[12]

DOC has shownreinforcing effects, includingconditioned place preference (CPP) andself-administration, in rodents similarly tomethamphetamine.[13] This is analogous to other findings in which various2C andNBOMedrugs have been found to producedopaminergic elevations and reinforcing effects in rodents.[14][15][16][17][18][19][20] Conversely however, in contrast toamphetamines like(–)-cathinone but similarly tomescaline,DOM has shown nostimulant-like or reinforcing effects inrhesus monkeys.[21][22][23][24]

Chemistry

[edit]

DOC is asubstitutedalpha-methylatedphenethylamine, a class of compounds commonly known asamphetamines. The phenethylamine equivalent (lacking the alpha-methyl group) is2C-C. DOC has astereocenter and (R)-(−)-DOC is the more activestereoisomer.

Detection in biological specimens

[edit]

DOC may be quantitated in blood, plasma or urine by gas chromatography-mass spectrometry or liquid chromatography-mass spectrometry to confirm a diagnosis of poisoning in hospitalized patients or to provide evidence in a medicolegal death investigation. Blood or plasma DOC concentrations are expected to be in a range of 1–10 μg/L in persons using the drug recreationally, >20 μg/L in intoxicated patients and >100 μg/L in victims of acute overdosage.[25]

Society and culture

[edit]

Popularity

[edit]

Although rare on theblack market, it has been available in bulk and shipped worldwide by select elite "Grey Market" Research Chemical suppliers for several years. Sales of DOC onblotting paper and in capsules was reported in late 2005 and again in late 2007. According to theDEA's Microgram from December 2007, the Concord Police Department in Contra Costa County, California, in the US, seized "a small piece of crudely lined white blotter paper without any design, suspectedLSD 'blotter acid'". They added "Unusually, the paper appeared to be hand-lined using two pens, in squares measuring approximately 6 x 6millimeters. The paper displayed fluorescence when irradiated at 365nanometers; however, color testing for LSD withpara-dimethylaminobenzaldehyde (Ehrlich's reagent) was negative. Analysis of a methanol extract by GC/MS indicated not LSD but rather DOC (not quantitated but a high loading based on the TIC)".[26] DOC is sometimes misrepresented as LSD by unscrupulous dealers. This is particularly dangerous, as DOC is not known to have the safety profile of LSD. It can be particularly unsafe, in comparison to LSD, for those suffering fromhypertension, as amphetamine compounds are known to cause sharp increases in systolicblood pressure.

Legal status

[edit]

International

[edit]

In December 2019, theUNODC announced scheduling recommendations placing DOC into Schedule I alongside another severalresearch chemicals.[27]

Australia

[edit]

Unscheduled but can be controlled as schedule II as an analogue of DOB.[28]

Canada

[edit]

Listed as aSchedule 1[29] as it is an analogue of amphetamine.[30] The CDSA was updated as a result of the Safe Streets Act changing amphetamines from Schedule 3 to Schedule 1.[31]

China

[edit]

As of October 2015 DOC is a controlled substance in China.[32]

Denmark

[edit]

Denmark added DOC to the list of Schedule I controlled substances as of 8.4.2007.[28]

Germany

[edit]

Scheduled in Anlage I since 22.1.2010.[28]

New Zealand

[edit]

Scheduled.[28]

Sweden

[edit]

Sveriges riksdag added DOC to schedule I ("substances, plant materials and fungi which normally do not have medical use") as narcotics in Sweden as of Aug 30, 2007, published byMedical Products Agency in their regulation LVFS 2007:10 listed as DOC, 4-klor-2,5-dimetoxi-amfetamin.[33]DOC was first classified bySveriges riksdags health ministryStatens folkhälsoinstitut as "health hazard" under the actLagen om förbud mot vissa hälsofarliga varor (translatedAct on the Prohibition of Certain Goods Dangerous to Health) as of Jul 1, 2004, in their regulation SFS 2004:486 listed as 4-klor-2,5-dimetoxiamfetamin (DOC).[34]

United Kingdom

[edit]

Class A.[28]

United States

[edit]

DOC is not scheduled or controlled at the federal level in theUnited States,[35] but theDepartment of Justice considers it to be an analogue ofDOB[36] and, as such, possession or sale could be prosecuted under theFederal Analogue Act.[28] In December 2023, the USDrug Enforcement Administration issued anotice of proposed rulemaking that would classify both 2,5-dimethoxy-4-chloroamphetamine and2,5-dimethoxy-4-iodoamphetamine as schedule I controlled substances.[37]

In the United States, the analoguesDMA,DOB, andDOM are Schedule Icontrolled substances.

Florida
[edit]

DOC is a Schedule Icontrolled substance in the state ofFlorida making it illegal to buy, sell, or possess.[38]

See also

[edit]

References

[edit]
  1. ^Anvisa (2023-07-24)."RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese).Diário Oficial da União (published 2023-07-25).Archived from the original on 2023-08-27. Retrieved2023-08-27.
  2. ^Shulgin A, Shulgin A (September 1991).PiHKAL: A Chemical Love Story. United States: Transform Press. p. 978.ISBN 0-9630096-0-5.Archived from the original on 3 January 2010. Retrieved30 November 2009.
  3. ^abPalamar JJ, Fitzgerald ND (October 2025). "The Epidemiology of Recreational Use and Availability of DOC and DOI in the United States".J Psychoactive Drugs:1–10.doi:10.1080/02791072.2025.2570937.PMID 41065346.
  4. ^ab"Erowid DOC Vault: Dosage".Archived from the original on 2 May 2008. Retrieved22 April 2008.
  5. ^ab"Erowid Online Books: "PiHKAL" - #64 DOC".Archived from the original on 3 August 2018. Retrieved17 November 2005.
  6. ^Bucks J (25 April 2013).""Moment of madness": rare drug implicated in student death".The Saint. Archived fromthe original on 28 April 2013. Retrieved25 April 2013.
  7. ^Barnett RY, Baker DD, Kelly NE, McGuire CE, Fassette TC, Gorniak JM (October 2014)."A fatal intoxication of 2,5-dimethoxy-4-chloroamphetamine: a case report".Journal of Analytical Toxicology.38 (8):589–91.doi:10.1093/jat/bku087.PMID 25217551.
  8. ^"PDSP Database".UNC (in Zulu). Retrieved1 February 2025.
  9. ^Liu T (1990)."BindingDB BDBM50013000 CHEMBL8100".Journal of Medicinal Chemistry.33 (3):1032–1036.doi:10.1021/jm00165a023.PMID 2308135. Retrieved1 February 2025.
  10. ^abEshleman AJ, Forster MJ, Wolfrum KM, Johnson RA, Janowsky A, Gatch MB (March 2014)."Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function".Psychopharmacology (Berl).231 (5):875–888.doi:10.1007/s00213-013-3303-6.PMC 3945162.PMID 24142203.
  11. ^Rudin D, Luethi D, Hoener MC, Liechti ME (2022)."Structure-activity Relation of Halogenated 2,5-Dimethoxyamphetamines Compared to their α‑Desmethyl (2C) Analogues".The FASEB Journal.36 (S1) fasebj.2022.36.S1.R2121.doi:10.1096/fasebj.2022.36.S1.R2121.ISSN 0892-6638.
  12. ^Halberstadt AL, Chatha M, Klein AK, Wallach J, Brandt SD (May 2020)."Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species"(PDF).Neuropharmacology.167 107933.doi:10.1016/j.neuropharm.2019.107933.PMC 9191653.PMID 31917152.
  13. ^Cha HJ, Jeon SY, Jang HJ, Shin J, Kim YH, Suh SK (May 2018). "Rewarding and reinforcing effects of 4-chloro-2,5-dimethoxyamphetamine and AH-7921 in rodents".Neurosci Lett.676:66–70.doi:10.1016/j.neulet.2018.04.009.PMID 29626650.
  14. ^Gil-Martins E, Barbosa DJ, Borges F, Remião F, Silva R (June 2025)."Toxicodynamic insights of 2C and NBOMe drugs - Is there abuse potential?".Toxicol Rep.14 101890.Bibcode:2025ToxR...1401890G.doi:10.1016/j.toxrep.2025.101890.PMC 11762925.PMID 39867514.
  15. ^Kim YJ, Ma SX, Hur KH, Lee Y, Ko YH, Lee BR, et al. (April 2021). "New designer phenethylamines 2C-C and 2C-P have abuse potential and induce neurotoxicity in rodents".Arch Toxicol.95 (4):1413–1429.Bibcode:2021ArTox..95.1413K.doi:10.1007/s00204-021-02980-x.PMID 33515270.
  16. ^Custodio RJ, Sayson LV, Botanas CJ, Abiero A, You KY, Kim M, et al. (November 2020). "25B-NBOMe, a novel N-2-methoxybenzyl-phenethylamine (NBOMe) derivative, may induce rewarding and reinforcing effects via a dopaminergic mechanism: Evidence of abuse potential".Addict Biol.25 (6) e12850.doi:10.1111/adb.12850.PMID 31749223.
  17. ^Seo JY, Hur KH, Ko YH, Kim K, Lee BR, Kim YJ, et al. (October 2019). "A novel designer drug, 25N-NBOMe, exhibits abuse potential via the dopaminergic system in rodents".Brain Res Bull.152:19–26.doi:10.1016/j.brainresbull.2019.07.002.PMID 31279579.
  18. ^Jo C, Joo H, Youn DH, Kim JM, Hong YK, Lim NY, et al. (November 2022)."Rewarding and Reinforcing Effects of 25H-NBOMe in Rodents".Brain Sci.12 (11): 1490.doi:10.3390/brainsci12111490.PMC 9688077.PMID 36358416.
  19. ^Lee JG, Hur KH, Hwang SB, Lee S, Lee SY, Jang CG (August 2023). "Designer Drug, 25D-NBOMe, Has Reinforcing and Rewarding Effects through Change of a Dopaminergic Neurochemical System".ACS Chem Neurosci.14 (15):2658–2666.doi:10.1021/acschemneuro.3c00196.PMID 37463338.
  20. ^Kim YJ, Kook WA, Ma SX, Lee BR, Ko YH, Kim SK, et al. (April 2024). "The novel psychoactive substance 25E-NBOMe induces reward-related behaviors via dopamine D1 receptor signaling in male rodents".Arch Pharm Res.47 (4):360–376.doi:10.1007/s12272-024-01491-4.PMID 38551761.
  21. ^Fantegrossi WE, Murnane KS, Reissig CJ (January 2008)."The behavioral pharmacology of hallucinogens".Biochem Pharmacol.75 (1):17–33.doi:10.1016/j.bcp.2007.07.018.PMC 2247373.PMID 17977517.Despite the reasonably constant recreational use of hallucinogens since at least the early 1970s [44], the reinforcing effects of hallucinogens have not been widely investigated in laboratory animals. Indeed, one of the earliest studies on the reinforcing effects of drugs using the intravenous self-administration procedure in rhesus monkeys found that no animal initiated self-injection of mescaline either spontaneously or after one month of programmed administration [45]. Likewise, the phenethylamine hallucinogen 2,5-dimethoxy-4-methylamphetamine (DOM) was not effective in maintaining self-administration in rhesus monkeys [46]. Nevertheless, the hallucinogen-like phenethylamine 3,4-methylenedioxymethamphetamine (MDMA) has been shown to act as a reinforcer in intravenous self-administration paradigms in baboons [47], rhesus monkeys [48 – 50], rats [51] and mice [52].
  22. ^Canal CE, Murnane KS (January 2017)."The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens".J Psychopharmacol.31 (1):127–143.doi:10.1177/0269881116677104.PMC 5445387.PMID 27903793.One of the earliest studies on the reinforcing effects of drugs using the intravenous self-administration procedure in rhesus monkeys found that no animal initiated self-injection of mescaline either spontaneously or after one month of programmed administration, [...] (Deneau et al., 1969). The lack of mescaline self-administration stood in contrast to positive findings of self-administration of morphine, codeine, cocaine, amphetamine, pentobarbital, ethanol, and caffeine. A subsequent study with rhesus monkeys using 2,5-dimethoxy-4-methylamphetamine (DOM; Yanagita, 1986) provided similar results as the mescaline study. These findings have withstood the test of time, as the primary literature is virtually devoid of any accounts of self-administration of [classical hallucinogens (CH)], suggesting that there are very limited conditions under which laboratory animals voluntarily consume CH.
  23. ^Yanagita T (June 1986). "Intravenous self-administration of (-)-cathinone and 2-amino-1-(2,5-dimethoxy-4-methyl)phenylpropane in rhesus monkeys".Drug Alcohol Depend.17 (2–3):135–141.doi:10.1016/0376-8716(86)90004-9.PMID 3743404.
  24. ^Maguire DR (October 2024)."Evaluation of potential punishing effects of 2,5-dimethoxy-4-methylamphetamine (DOM) in rhesus monkeys responding under a choice procedure".Behav Pharmacol.35 (7):378–385.doi:10.1097/FBP.0000000000000787.PMC 11398979.PMID 39052019.
  25. ^Baselt RC (2014).Disposition of toxic drugs and chemicals in man. Seal Beach, California: Biomedical Publications. p. 2173.ISBN 978-0-9626523-9-4.
  26. ^"mg1207"(PDF). Archived fromthe original(PDF) on 2012-10-17. Retrieved2013-08-13.
  27. ^"December 2019 – WHO: World Health Organization recommends 12 NPS for scheduling".
  28. ^abcdef"Erowid DOC Vault: Legal Status".Archived from the original on 1 May 2008. Retrieved22 April 2008.
  29. ^"Schedule I".Controlled Drugs and Substances Act. Canadian Legal Information Institute. 2022-03-31.Archived from the original on 2022-03-31. Retrieved2022-03-31.
  30. ^"Controlled Drugs and Substances Act".Definitions and interpretations. Canadian Legal Information Institute. Archived fromthe original on 2013-11-10. Retrieved2022-03-31.
  31. ^"Backgrounder: The Safe Streets and Communities Act Four Components Coming Into Force".Canadian Department of Justice. Archived fromthe original on 2012-10-18.
  32. ^"关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived fromthe original on 1 October 2015. Retrieved1 October 2015.
  33. ^"Läkemedelsverkets föreskrifter - LVFS och HSLF-FS | Läkemedelsverket"(PDF).
  34. ^"Förordning om ändring i förordningen (1999:58) om förbud mot vissa hälsofarliga varor"(PDF) (in Swedish). 27 May 2004. Archived fromthe original(PDF) on 15 September 2018.
  35. ^"PART 1308 - Section 1308.11 Schedule I".www.deadiversion.usdoj.gov. Archived fromthe original on 27 August 2009. Retrieved31 March 2018.
  36. ^"DEA Resources, Microgram, October 2007"(PDF). Archived fromthe original(PDF) on 2012-10-17. Retrieved2012-10-03.
  37. ^"Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in Schedule I".www.regulations.gov.
  38. ^"The 2017 Florida Statutes - Title XLVI - CRIMES - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL".leg.state.fl.us. Retrieved31 March 2018.

External links

[edit]
Wikimedia Commons has media related to2,5-Dimethoxy-4-chloroamphetamine.
Tryptamines
No ring subs.
4-Hydroxytryptamines
5-Hydroxytryptamines
5-Methoxytryptamines
Other ring subs.
α-Alkyltryptamines
Others
Cyclized
Bioisosteres
Phenethylamines
Scalines
2C-x
3C-x
DOx
4C-x
Ψ-PEA
MDxx
FLY
25x-NB (NBOMes)
Others
Cyclized
Lysergamides
  • Bioisosteres:JRT
Others
Natural sources
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Phenethylamines
Amphetamines
Phentermines
Cathinones
Phenylisobutylamines
(and further-extended)
Catecholamines
(and close relatives)
Cyclized
phenethylamines
Phenylalkylpyrrolidines
2-Benzylpiperidines
(phenidates)
Phenylmorpholines
(phenmetrazines)
Phenyloxazolamines
(aminorexes)
Isoquinolines and
tetrahydroisoquinolines
2-Aminoindanes
2-Aminotetralins
Others / unsorted
Related compounds
Retrieved from "https://en.wikipedia.org/w/index.php?title=2,5-Dimethoxy-4-chloroamphetamine&oldid=1316574742"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp